FCG
MRNA icon

Fielder Capital Group’s Moderna MRNA Stock Holding History

Fielder Capital Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$210K Buy
+4,130
New +$193K 0.05% 272

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fielder Capital Group's MRNA Position: Q1 2026 in Review

Fielder Capital Group opened a new position in Moderna (MRNA) in Q1 2026: 4,130 shares worth $210K. The stake represents 0.05% of the portfolio and ranks #272 among its holdings.

723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Fielder Capital Group held 4,130 shares of Moderna worth $210K as of Q1 2026.
  • Moderna was a new Fielder Capital Group position in Q1 2026.
  • Moderna made up 0.05% of Fielder Capital Group's portfolio in Q1 2026, its #272 holding.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Fielder Capital Group's 13F filing for Q1 2026, filed 12 May 2026.